Scientists at Catholic University discuss research in cancer vaccines
2007 NOV 19 -- New investigation results, 'The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity,' are detailed in a study published in Vaccine. According to a study from Seoul, South Korea, "The gradual induction of immune responses by dendritic cell (DC) vaccination or the rapid decrease of adoptively transferred T cells may be major limitations in complete treatment of established tumors by active or passive immunization. The numbers of carcinoembryonic antigen (CEA)-specific T cells increased on 7th day and decreased from 2 weeks after repeated vaccination with CEA-peptide-pulsed DCs." "Adoptively transferred CEA-specific T cells were detectable on day 1 and reached their peak by day 4, and thereafter decreased. On the basis of these results, a combined immunotherapy of DC vaccination following adoptive T cell transfer was performed to overcome these limitations of each modality. The injection of DCs within 1 day after adoptive T cell transfer showed a synergistic effect. However, when the DC vaccine was administered on day 3 or 7, CEA-specific T cells gradually declined. This concomitant immunization significantly inhibited the tumor growth than the DC vaccine administered on day 3 or 7 in 10 days tumor model. Moreover, the concomitant immunization showed potent anti-tumor effects resulting in complete inhibition of tumor growth in 2 days tumor model," wrote M.Y. Park and colleagues, Catholic University. The researchers concluded: "These results suggest that the optimal interval for the DC vaccination following adoptive T cell transfer is important for boosting antigen-specific T cell responses and this combined immunotherapy may provide a potent therapeutic strategy for cancer treatment." Park and colleagues published their study in Vaccine (The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity. Vaccine, 2007;25(42):7322-30). For more information, contact M.Y. Park, Catholic University of Korea, Dept. of Microbiology and Immunology, 505 Banpo-Dong, Seocho-Gu, Seoul 137-701, South Korea. Publisher contact information for the journal Vaccine is: Elsevier Science Ltd., the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. Keywords: South Korea, Seoul, Cancer Vaccines, Anticancer Therapy, Biotechnology, Immunotherapy, Therapy, Treatment, Vaccines. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
